Praxis Precision Medicines

Update in progress

PRAX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on CNS disorders marked by neuronal excitation–inhibition imbalance in the United States. It uses its Cerebrum small-molecule platform for orally available CNS therapies and Solidus to discover antisense oligonucleotides. Its pipeline includes ulixacaltamide, relutrigine, vormatrigine, and Elsunersen in NDA/Phase 2/3 trials, plus preclinical PRAX programs. Based in Boston, founded 2015.

Company score

Sentiment: 0.46; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.45; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.02; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.14; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.30; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive